Trial Profile
Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 12 Feb 2015 One more end point ''Number of headache days with moderate or severe intensity'' added to the study, hence trial focus of the study also got changed to include Therapeutic use, as reported by ClinicalTrials.gov record.
- 12 Feb 2015 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.